HHC
TEVA icon

Hutchin Hill Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Hutchin Hill Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-75,000
Closed -$2.72M – 1031
2016
Q4 		$2.72M Sell
75,000
-35,000
-32% -$1.4M 0.09% 272
2016
Q3 		$5.06M Buy
110,000
+35,000
+47% +$1.83M 0.1% 113
2016
Q2 		$3.77M Buy
75,000
+50,000
+200% +$2.66M 0.13% 113
2016
Q1 		$1.34M Buy
+25,000
New +$1.47M 0.04% 365

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hutchin Hill Capital's TEVA Position: Q3 2017 in Review

Hutchin Hill Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 83,300 shares — an estimated $2.77M sold.

Hutchin Hill Capital first reported a position in TEVA in Q3 2016 and held it in 4 quarters. The position peaked at $17.3M in Q3 2016. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Hutchin Hill Capital reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 83,300 Teva Pharmaceuticals shares in Q3 2017, an estimated $2.77M.
  • Hutchin Hill Capital first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Hutchin Hill Capital's Teva Pharmaceuticals position peaked at $17.3M in Q3 2016.
  • 536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.